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ABSTRACT 
 
Objective: To evaluate the predictive value of genetic polymorphisms in the context of 
BCG immunotherapy outcome and create a predictive profile that may allow discriminating the 
risk of recurrence. 
 Material and Methods: In a dataset of 204 patients treated with BCG, we evaluate 42 
genetic polymorphisms in 38 genes involved in the BCG mechanism of action, using Sequenom 
MassARRAY technology. Stepwise multivariate Cox Regression was used for data mining.  
Results: In agreement with previous studies we observed that gender, age, tumor 
multiplicity and treatment scheme were associated with BCG failure. Using stepwise multivariate 
Cox Regression analysis we propose the first predictive profile of BCG immunotherapy outcome 
and a risk score based on polymorphisms in immune system molecules (SNPs in TNFA-1031T/C 
(rs1799964), IL2RA rs2104286 T/C, IL17A-197G/A (rs2275913), IL17RA-809A/G (rs4819554), 
IL18R1 rs3771171 T/C, ICAM1 K469E (rs5498), FASL-844T/C (rs763110) and TRAILR1-397T/G 
(rs79037040) in association with clinicopathological variables. This risk score allows the 
categorization of patients into risk groups: patients within the Low Risk group have a 90% chance 
of successful treatment, whereas patients in the High Risk group present 75% chance of 
recurrence after BCG treatment.  
Conclusion: We have established the first predictive score of BCG immunotherapy 
outcome combining clinicopathological characteristics and a panel of genetic polymorphisms. 
Further studies using an independent cohort are warranted. Moreover, the inclusion of other 
biomarkers may help to improve the proposed model. 
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INTRODUCTION 
 
Bladder Cancer (BC) is the most common malignancy of the urinary tract [1] and has the 
highest lifetime treatment costs per patient of all cancers [2]. In Europe, BC is the fourth most 
common cancer in men and the eighth most common cause of cancer-specific mortality [1]. At the 
time of diagnosis, 75-80% of cancers are non-muscle invasive BC (NMIBC) tumors of stages pTa, 
pT1 or Carcinoma in situ (CIS). After transurethral resection (TUR), these tumors present high 
recurrence and progression rates at five years [3]. TUR followed by intravesical instillation of 
bacillus Calmette-Guerin (BCG) has delayed the recurrence and is currently considered the most 
effective treatment for intermediate and high risk of recurrence/progression NMIBC tumors [3]. 
However, several studies have demonstrated that 30% to 50% of the patients fail to respond to 
this therapeutic and in such cases the tumor may become more aggressive [4, 5]. Therefore, it is 
important to find biomarkers that may accurately determine treatment outcome and/or a profile 
that could identify patients at elevated risk of treatment failure. 
The exact mechanism of BCG immunotherapy antitumor activity is not well known [6]. 
The initial event comprehends the attachment of BCG to matrix fibronectin at sites of urothelial 
disruption [7, 8]. Subsequently the bacillus is internalised and bacterial antigens are presented by 
either tumor cells or APC (antigen presenting cells), such as macrophages, B-lymphocytes and 
dendritic cells [8, 9]. These events induce the production of various cytokines and chemokines 
including interferon-γ (IFN-γ), interleukin-1 (IL-1), IL-2, IL-5, IL-6, IL-8, IL-10, IL-12, IL-18 and tumor 
necrosis factor-α (TNF-α) that  mediate the initiation and maintenance of the inflammatory 
process that contributes to eliminate residual tumor cells [6, 10]. Qualitative analyses of BCG A
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treatment-associated immune responses indicate that the effective establishment of a Th1-
cytokine profile is crucial for an effective antitumor activity [6, 10, 11]. The importance of the 
Th1/Th2-dichotomy is further supported by observations that high expression levels of 
immunoregulatory or Th2-cytokines, like IL-10, arrest Th1-cytokine responses and abrogate the 
therapeutic effect of BCG [12]. Experimental evidence further support that tumor cells may be 
eliminated directly by the bacillus upon its internalization by the production of iNOS or by the 
effector cells such as cytotoxic T-cells, via perforin or TRAIL [13-15].  These observations also 
reinforce the notion that alterations in these pathways may influence treatment outcome.  
Several markers associated with BCG immunotherapy response have been appointed, and 
some authors suggest an important role for functional polymorphisms (SNPs) in key genes of 
immune system and inflammatory response [6, 16, 17]. In  agreement with these observations, 
we have recently presented evidence that a polymorphism in FASL may influence treatment 
outcome [18].  Therefore, a deeper investigation of functional SNPs in genes involved in different 
steps of BCG mechanism of action, such as antigen presentation, cytokines and chemokines 
production and tumor elimination, is regarded crucial to define a therapy failure profile. Our aim 
is to evaluate genetic polymorphisms as potential predictive biomarkers and, in combination with 
clinicopathological characteristics, establish a predictive profile of BCG immunotherapy outcome. 
  
 
MATERIAL AND METHODS  
 
Population 
 
In this retrospective case-control study, all intermediate and high-risk NMIBC patients (T1, 
high grade, multiple Ta/T1, CIS) who underwent transurethral resection followed by BCG therapy 
between 1998 and 2009 at the Portuguese Institute of Oncology – Porto were eligible for this A
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study. A total of 204 blood samples were collected during 2006 and 2012 on patient’s follow-ups.  
All patients received intravesical instillation of BCG for 6 consecutive weeks starting 2-3 weeks 
after surgery, i.e., induction scheme (iBCG) and the majority underwent further instillations every 
3 months for two years, i.e., maintenance scheme (mBCG). All the patients in the iBCG group 
completed the 6 instillation scheme and includes patients treated before the implementation of 
European Association of Urology guidelines recommending the mBCG scheme [19] or patients 
showing significant intolerance to prolonged BCG treatment. The treatment age of the patients 
was 64.19±9.99 (min:37; max:84) years, with a male:female sex ratio of 175:29. The patients were 
followed by cystoscopy and urinary cytology every 3 months for the first year, every 6 month for 
the second year and every 12 months thereafter. The median follow-up time was 57 months 
(from 8 till 163 months). Tumor recurrence was defined  new tumor in the bladder, after 
treatment, confirmed by pathology, with at least one tumor-free cystoscopy in-between. The end 
point of the study, termed recurrence-free survival (RFS), was defined as the period between the 
beginning of BCG treatment until the date of the most recent cystoscopy or recurrence. Since only 
9% of the patients presented progression by stage/grade, this endpoint was not considered in this 
work. All clinicopathological information was obtained from patients’ clinical records. Informed 
and written consent from each patient was obtained. The institutional ethics committee approved 
the study. 
 
DNA extraction and genotyping 
 
Peripheral blood samples were collected following standard venipuncture technique in 
EDTA-containing tubes, and the DNA was extracted from the white blood cell fraction using a 
salting out protocol [20] and stored at -20ºC.  A
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A total of 42 SNPs in 38 genes involved in the various steps of BCG immunotherapy 
mechanism of action were selected based in the following criteria: i) have putative or published 
functional implication in molecule expression, ii) have a minor allele frequency of 15% (Table S1). 
Gene polymorphisms were determined using a Sequenom MassARRAY system (San Diego, 
CA, USA). The genotyping was undertaken using the SequenomiPLEX platform, according to the 
manufacturer’s instructions (Sequenom, San Diego, CA, USA). The detection of SNP was carried 
out by analyzing the primer extension products generated from previously amplified genomic 
DNA using a Sequenom chip-based matrix-assisted laser desorption/ionization time-of-flight 
(MALDI-TOF) mass spectrometry platform. Sequenom Assay Design 3.1 software was used to 
design the primers for polymerase chain reaction (PCR) amplification and single base extension 
assays (Sequenom, San Diego, CA, USA) according to the manufacturer’s instructions. This 
technique was carried-out by the Genomics Unit from the Genotyping Service of Instituto 
Gulbenkian de Ciência (IGC) (Oeiras, Portugal). 
Genotyping data was read blindly until the study endpoint. For quality control, 10% of the 
samples were randomly selected for a second analysis and 100% of concordance was observed. 
Genotyping of approximately 10% of the evaluated SNPs were repeated using TaqMan allelic 
discrimination assays for real time PCR and presented 100% concordance with the Sequenom 
MassARRAY genotyping.  
 
Statistical analysis 
 
Statistical data analysis was carried out using the computer software IBM Statistical 
Package for Social Sciences—SPSS for Windows (version 22.0; IBM, Armonk, NY, USA). Chi-square 
analysis was used to compare categorical variables. Kaplan-Meier survival curves were used to 
evaluate correlation between genotypes and RFS and were compared by log-rank statistical test. 
Further, multivariate Cox regression analysis was used to assess the effect of individual A
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polymorphisms on the time to recurrence in BCG-treated patients and to adjust for potential 
confounders.   
Stepwise multivariate Cox regression with backward elimination (P-value for retention 
=0.10) was conducted in all clinical pathological characteristics. A similar approach was applied for 
genetic variants, including all polymorphisms with aHR <0.6 or aHR >1.4 (40% decrease or 
increase in odds of the outcome; Table S2). The variables that remained in the two previous 
models were inserted in another stepwise multivariate Cox regression with backward elimination 
to create a combined (clinical and genetic variables) model. The concordance (c) index was used 
to compare the predictive ability of the three Cox regression models, with c>0.5 being considered 
with a good prediction ability [21]. 
We constructed an inclusive multi-locus genetic risk score for each participant by 
summing the coefficients for each of the resulting variables after stepwise regression analyses. 
For each SNP, the risk genotypes were coded as 1 and the non-risk alleles as 0. The model was 
determined by multiplying the β coefficients (Hazard Ratios) by the SNPs and the clinico-
pathological variables included in the model. Parsimonious risk scores were calculated based on 
the models that included separately the clinicopathological and the genetic variables. 
We assessed the clinical value of the above three scores to correctly predict disease status 
by receiver operating characteristic (ROC) curve analysis. The comparison of the areas under the 
ROC curves (AUC) constructed with the scores (with and without genetic information) was 
performed.  Risk groups were created based in the best sensitivity/specificity ratio, as well as, the 
best negative and positive predictive values (NPV and PPV) possible of the best predictive model. 
 
 
RESULTS 
 
Clinicopathological features and BCG treatment outcome A
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The 204 evaluated cases presented a recurrence after BCG treatment of 34.3%. The 
median time to recurrence was 29.5 months (range: 8.0-122.0), whereas for patients without 
recurrence the median follow-up time was 68.5 months (range: 12.0-163.0). Table 1 presents 
patients and tumour clinicopathological characteristics and its association with treatment 
response and RFS after BCG treatment.  
Our results show that patients over 65 years have approximately 2-fold increased risk of 
recurrence (HR=1.973, [1.212-3.212], p=0.006). Moreover, it was observed that men have a 2.5-
fold increased risk of recurrence (HR=2.533, [1.018-6.303], p=0.046). Furthermore, patients 
treated only with iBCG showed a 2-fold risk of recurrence (HR=2.034, [1.270-3.256], p=0.003). We 
performed a stepwise Cox regression analysis using backward elimination and evaluated all the 
clinicopathological features (gender, age, tumour stage, grade, multifocality, size, CIS presence 
and prior recurrence and treatment scheme) in terms of recurrence after BCG treatment. Only 
gender, age, tumor multifocality and treatment scheme remained independently associated to 
BCG outcome. The variables retained by this analysis were termed as Model 1 in the predictive 
model establishment phase. These variables were considered as possible confounders and were 
used as covariates in the subsequent analysis. 
 
 
Genetic polymorphisms and BCG treatment outcome 
 
Antigen presentation 
In this study we evaluated five polymorphisms in genes involved in antigen presentation. 
From the studied SNPs, only patients carrying GG genotype for ICAM1 rs5498 presented a 2-fold 
risk of recurrence after BCG treatment (aHR=1.759, [1.050-2.949], p=0.032; Table 2). In terms of 
RFS, using Kaplan-Meier analysis, a trend was observed for this SNP. Patients carrying GG A
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genotype had a mean RFS of 80 months, whereas patients carrying AA and GA genotype 
presented a mean RFS of 116 months (log rank, p=0,07; Fig. 1A).  
 
Cytokines and chemokines 
We evaluated 33 polymorphisms in 29 cytokine/chemokine genes and its receptors (Table 
S1 e S2). Our results have demonstrated that IL2RA rs2104286 C/T, IL17A rs2275913 (-197G/A), 
TNFA rs1799964 (-1031T/C) and CCR2 rs391835 G/A (V64I) were associated with BCG treatment 
outcome. As showed in table 2, an increased risk of recurrence was found in patients carrying the 
variants of the mentioned polymorphisms (IL2RA rs2104286 CC vs.CT: aHR=2.007, [1.207-3.335], 
p= 0.007; IL17A rs2275913 GG+GA vs. AA: aHR=2.097, [1.118-3.993], p= 0.021; TNFA rs1799964 
TT+TC vs.CC: aHR=2.427, [1.144-5.149], p= 0.021; CCR2 rs391835 GG vs. GA+AA: aHR=2.197, 
[1.120-4.312], p=0.022). Individuals carrying each of these genotypes presented lower recurrence 
free survival (log rank p<0.05; Fig. 1B-E) 
 
Effectors molecules 
We also evaluated iNOS gene, due to its involvement in the direct killing of tumor cells 
upon BCG internalization as well as the TRAIL and its receptor TRAILR1, that are important 
mediators of cell death promoted by neutrophils and cytotoxic T-cell. Our analysis demonstrated 
that only patients carrying G allele (GG or TG genotypes) of TRAILR1 had a 3-fold risk of 
recurrence (TT vs. TG+GG, aHR=3.195, [1.373-7.433], p= 0.007; Table 2). In terms of RFS, we found 
differences when we compared patients carrying the GG or TG genotypes with the ones with TT 
genotype (log-rank, p=0.018; Fig 1F). 
 
 
Establishment of predictive models of BCG immunotherapy outcome 
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To determine the best predictive model of BCG outcome, we compared a clinical, a 
genetic and a combined model using stepwise Cox regression analysis (Table 3).  
The concordance (c) index was used to compare the predictive ability of each model; the 
predictive value was assessed with Harrell’s concordance indexes, where a c-index of 1 indicates 
perfect concordance [21]. The predictive model using clinicopathological characteristics 
mentioned earlier presented a c-index of 0.698 (Model  1, Table 3).  
To test if genetic variability in functional SNPs in molecules involved in BCG treatment 
mechanism could contribute to a combined effect for treatment outcome, we estimated the 
overall mutually-adjusted effects by stepwise multivariate Cox regression (Model 2). The SNPs in 
TNFA-1031T/C (rs1799964), IL4-33T/C (rs2070874), IL2RA rs2104286 T/C, IL17A-197G/A 
(rs2275913), IL17RA-809A/G (rs4819554), IL18R1 rs3771171 T/C, IL6R Asp358Ala (rs8192284), 
ICAM1 K469E (rs5498), FASL-844T/C (rs763110) and TRAILR1-397T/G (rs79037040) remained 
independently associated with risk of recurrence after BCG immunotherapy and this model 
presented a c-index of 0.735 (Table 3). 
To evaluate the combined effect of clinicopathological features and genetic variants in 
BCG immunotherapy outcome we performed stepwise multivariate Cox regression with the 
variables obtained in the two previous models. Age and the IL6R polymorphism were removed 
from the combined model (Model  3) and the c-index of this model was 0.821 (Table 3). 
The linear risk scores were computed based on the above Cox regression models and 
tested as overall risk predictors. Figure 2 shows the ROC curves for the risk scores of each model. 
The AUC estimates for the risk score of Model 3 was higher than the two other risk scores (Model 
1, AUC: 0.684; Model 2, AUC: 0.734; Model 3, AUC:0.820). 
Risk groups stratification was performed based on the best cut-off values to obtain the 
highest sensitivity and specificity (approximately 90%). Three risk groups have been created based 
on the best predictive model (Model 3), as shown in Table 5. Patients within Low Risk group 
representing approximately 44% of all patients presented a negative predictive value of 92.2%, A
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meaning that patients with a risk score below 17.2 had approximately 92% chance to have a 
successful BCG treatment. On the other hand, the High Risk group had a positive predictive value 
of 75.6% and represented 22% of all patients treated with BCG immunotherapy. This 
encompasses patients with a risk score above 21.1, which have approximately 76% chance of BCG 
treatment failure. Moreover patients with a score within the two mentioned cut-off values were 
placed in the Intermediate Risk group, which have a 42% chance of treatment failure. 
Kaplan-Meier plots showed significant differences in terms of RFS, for patients belonging 
to the different risk groups (Log-rank, p=0.0001, Fig. 3). Patients in the High risk group presented 
recurrence at the median time of 32 months, whereas patients in the Intermediate Risk group 
recurred at 93 months. Moreover, patients in the Low risk groups presented a mean time to 
recurrence of 140 months. Cox regression analysis showed that patients in the Intermediate and 
High risk groups have a substantial increase in recurrence risk (Intermediate Risk: HR=6.58, [2.88-
15.05], p<0.001; High Risk: HR=18.7, [8.24-42.6], p=<0.001; Table 5). 
 
DISCUSSION 
 
Intravesical immunotherapy with BCG is the gold standard therapeutics for NMIBC at 
intermediate/high of recurrence or progression [3]. Nevertheless, approximately 30% of the 
patients recur after the treatment and 15% progress to muscle-invasive disease associated with 
poor prognosis [4]. Several clinicopathological characteristics influence the course of treatment, 
however there is no consensus regarding its predictive value [22]. Furthermore, there are no 
biomarkers to assess the outcome, making impossible the early identification of patients that 
could be better served by alternative treatments [16, 22]. 
Our previous reports using a smaller dataset have demonstrated that age, tumor 
multiplicity and the treatment scheme are associated with treatment failure [18, 23-25]. Herein, 
with a larger sample, we confirmed that patients either with age over 65 years, or with multiple A
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tumors, or treated only with induction scheme were at risk of treatment failure. We also observed 
that male patients presented an increased risk of recurrence after treatment. Our findings 
reinforce previous associations of these clinical variables with BCG immunotherapy response [18, 
22-25] and highlight the need to include them in predictive models for this therapeutics.   
Genetic polymorphisms in molecules involved in the BCG mechanism of action have also 
been appointed as good candidates to predict treatment outcome. Nevertheless, only few 
polymorphisms have been studied, individually and in small sample sets, mainly using non-
integrative approaches [16, 26-28]. In an attempt to establish a predictive model of treatment 
response we have evaluated 42 functional SNPs in 38 genes of molecules involved in the several 
steps of BCG immunotherapy mechanism of action.  
Among molecules implicated in antigen presentation, only ICAM1 K469E polymorphism 
was associated with BCG outcome. This is the first study evaluating the role of ICAM-1 SNPs in 
BCG immunotherapy context. ICAM-1 (Intercellular Adhesion Molecule-1) is a transmembrane 
protein involved in adhesion of antigen-presenting cells to T lymphocytes, that upon binding 
enhances proinflammatory signals such as inflammatory leukocyte recruitment [29]. Interestingly, 
circulating forms of ICAM-1 (sICAM1) were found to inhibit the interaction between T cells and 
tumors [30], and block NK cell-mediated toxicity [31]. The ICAM1 K469E polymorphism has been 
recognized to affect sICAM-1 levels and individuals carrying the GG genotype of this SNP have 
been found to present higher levels of sICAM-1 and consequently a decreased immune response 
[32]. Our results now show that patients carrying this genotype present a higher risk of BCG 
failure. Therefore, we postulate that higher levels of sICAM-1 may inhibit BCG antigen 
presentation and T-cell interaction with bladder tumor cells, reducing the cytotoxic effect of BCG 
immunotherapy. 
We also evaluated several SNPs in cytokines, chemokines genes and its receptors and 
found that patients carrying the AA genotype of IL17-197G/A polymorphism presented an 
increased risk of recurrence after BCG treatment. It was recently described that IL-17 (also known A
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as IL-17A), a T-cell-derived proinflammatory cytokine, is produced by γδ T-cells and plays a key 
role in the BCG-induced recruitment of neutrophils to the bladder, which is essential for the 
antitumor activity against bladder cancer [33]. The presence of AA genotype of IL17-197G/A 
polymorphism has been associated to reduced the levels of this molecule [34], therefore 
explaining its association with decreased response to treatment. 
At the moment, IL-2 urinary levels are recognized as the most promising predictive 
biomarker of BCG treatment response. However, this molecule can only be measured during the 
treatment period and therefore cannot be used previously in the treatment definition [16]. 
Therefore, we evaluate genetic polymorphisms that may exert some effect in IL-2 production and 
its receptor. Among the SNPs evaluated only IL2RA SNP was associated with BCG immunotherapy 
outcome. Studies revealed that patients carrying C allele of IL2RA rs2104286 presented lower 
production of soluble IL-2Rα and reduced T-cell activation [35]. Since we found that patients 
carrying this allele presented higher risk of recurrence, we may hypothesize that T-cell activation 
through IL-2 may be diminished in this population, compromising a key role feature of BCG 
mechanism of action.  
Due to the important role of TNF-α in the establishment of a Th1 immune response, we 
evaluated functional polymorphisms in TNFA gene. We found that TNFA-1031T/C was associated 
with recurrence after BCG treatment. This SNP has been evaluated in a previous study in the 
context of BCG treatment outcome [26], however showing contradicting results. According to the 
authors the CC genotype was associated with a protective effect whereas we observed an 
association with increased risk of recurrence. These differences may be explained by either the 
different ethnicities of the populations; a bias of the sample number, since the number of patients 
that we evaluated was significantly higher (204 vs 70); or the inclusion of patients treated with 
mBCG in our study, since the treatment scheme was not considered in referred study.  
We and others have reported that macrophages play a key role in BCG mechanism of 
action [6, 23, 36]. Therefore, we elected to evaluate polymorphisms in genes involved in A
cc
ep
te
d 
A
rti
cl
e
14 
This article is protected by copyright. All rights reserved. 
macrophage attraction and activation, such as, monocyte chemoattractant protein-1 (MCP-1) that 
acts as a chemoattractant for monocytes, macrophages and other inflammatory cells to sites of 
inflammation [37] and its receptor (CCR2). Among the studied SNPs only the CCR2-960T/A 
polymorphism demonstrated an association with treatment outcome. This SNP is located within 
the functional promoter [38] and patients carrying A allele have been described to present 
reduced monocyte migration activity [39]. Moreover, our results showed that patients carrying 
this allele had an increased risk of recurrence possible due to a deficient monocyte migration. This 
would result in decreased macrophage attraction which would ultimately influence the 
immunological activation promoted by BCG therapy. 
Another line of evidence indicates that neutrophils play an important part in BCG 
immunotherapy, especially through the release of tumor necrosis factor-related apoptosis-
inducing ligand (TRAIL). This molecule is one of the key effectors of BCG antitumor action [14]. 
Therefore we evaluated genetic polymorphisms that could influence TRAIL expression as well as 
its receptor. Our results demonstrated that patients carrying the G allele of TRAILR1-397T/G 
polymorphism had an increased risk of recurrence after BCG treatment. According to Wang et al. 
the presence of this allele increases the transcriptional activity of TRAILR1 promoter, possibly 
leading to higher expression of the receptor [40]. Although an increased expression of TRAILR1 
may improve death receptor activation in BC cells promoted by BCG, the higher expression of this 
receptor in T-cells may enhance T-cell apoptosis, especially in T helper (Th) 1 cell clones which are 
sensitive to TRAIL-induced apoptosis [41]. Moreover, the activation of T cells with interleukin (IL)-
2 resulted in TRAIL susceptibility and TRAIL caused death of antigen-specific memory CD8+ T cells 
[41]. Taking in account all these facts, we may postulate that an increased expression of this 
receptor, enhanced by TRAILR1-397T/G polymorphism may lead to higher TRAIL-induced T-cell 
apoptosis, compromising BCG immunotherapy efficacy.  
The work of Leibovici et al., in 2005, was the first to evaluate genetic polymorphisms in 
the context of BCG treatment response [42]. This study screened 123 patients treated with BCG A
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for polymorphisms in TNFA, IL6 and IL8 genes and found that only the IL6-174G/C polymorphism 
was associated with an higher risk of recurrence after BCG immunotherapy [42]. Moreover, 
Ahirwar and colleagues found that IL6-174G/C and IL8-251T/A polymorphisms were associated 
with a reduced risk of recurrence in their population [27, 43]. In the present study we also 
evaluated these SNPs but did not found a significant association with recurrence. These 
differences may arise from different genetic backgrounds in the studied populations (American, 
European  and Asian populations).  
In resume, the effects exerted by the SNPs associated with treatment outcome contribute 
to impaired T-cell activation, reduced macrophage and neutrophil attraction, and Th1 cell 
apoptosis, all of them key mediators of tumor cell death. Our data suggests that the presence of 
several of these deleterious effects may contribute to an inefficient immune response and 
consequently BCG treatment failure.  
The main objective of this work was to establish a predictive profile of BCG 
immunotherapy outcome. We started by evaluating the influence of clinical variables and genetic 
variants separately and then in combination. We found that the association of clinicopathological 
and genetic information provides a good predictive model of recurrence after BCG treatment and 
the risk score created based in this model may be suitable to stratify patients based on their 
chances of a successful treatment. This is the first report combining several genetic 
polymorphisms that could influence BCG mechanism of action and also clinical variables. At the 
moment, the probability of recurrence is calculated based on the EORTC risk tables, which 
stratifies patients according to the risk of recurrence. Based on these tables, patients at 
intermediate and high risk of recurrence perform BCG immunotherapy. Moreover, the CUETO 
group created risk tables for BCG treated patients based in clinical and pathological characteristics 
[44]. Herein, we propose a predictive model and a risk score of recurrence after BCG treatment 
based in clinicopathological variables and the genetic variability of the host. This is a preliminary 
study, since no independent cohort was used for validation, but is important to highlight that the A
cc
ep
te
d 
A
rti
cl
e
16 
This article is protected by copyright. All rights reserved. 
proposed model could identify patients with 90% probability of successful treatment and 75% 
chance of recurrence, which is more accurate than the actual models. Noteworthy, we created a 
model based on information from more than 200 patients, which contrasts with the small 
populations used in previous studies involving genetic polymorphisms in the context of BCG 
immunotherapy (less than 70 patients). The established risk groups are expected to help clinical 
decision alone or in combination with the existing risk scores. However it should be noticed that 
patients that fall in the Intermediate Risk group present a 40% probability of recurrence that is 
similar to the recurrence chance without performing this risk stratification. More studies are 
needed to corroborate our findings in an independent dataset of patients from different 
population.  It is also necessary to include other potential markers, such as tumor markers, this 
may help to a better stratification of the patients.  
In conclusion, this work has allowed the identification of novel genetic markers of BCG 
immunotherapy outcome and the establishment of a genetic risk score in association with clinical 
and pathological characteristicscapable of stratifying patients according to the risk of recurrence 
after BCG immunotherapy. The established risk groups identify patients with poor prognosis and 
may constitute a helpful tool improve clinical decision. 
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FIGURES LEGENDS 
 
Figure 1 - Effect of the most significant polymorphisms in recurrence-free survival (RFS). Kaplan-
Meier analysis to evaluate the association between RFS in the studied patients and the genotypes 
of: A- ICAM1  rs5498 A/G (K469E); B- IL2RA rs2104286 C/T; C- IL17A rs2275913 (-197G/A); D- 
TNFA rs1799964 (-1031T/C); E- CCR2 rs391835 G/A (V64I); F- TRAILR1 rs13278062 (-397T/G). 
Comparison performed by log-rank test (A: p=0.070; B: p=0.013; C: p=0.005; D: p=0.039; E: 
p=0.032; F: p=0.018); + and  censored cases of each group analyzed. 
 
 
Figure 2 - ROC curves and AUC for the risk scores constructed based on the three different 
models. Solid line corresponds to the risk score of Model 3 (combination of clinicalpathological 
and genetic variables), dashed line represents the risk score of Model 2 (genetic variables alone) 
and dotted line refers to the risk score of Model 1 (Clinicopathological variables alone). Model 1, 
AUC: 0.684; Model 2, AUC: 0.734; Model 3, AUC:0.820. 
 
 
Figure 3 - Recurrence-free survival (RFS) of the patients within different risk groups based on 
the predictive Model 3. Kaplan-Meier analysis to evaluate the RFS of the studied patients within 
each risk group. Comparison performed by log-rank test (p<0.001); + Low Risk patients;  
censored Intermediate Risk patients;  censored High Risk patients. 
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Table 1. Relation between patients clinical and tumour characteristics and recurrence 
after BCG treatment. 
Variables Total BCG success BCG failure HR [95% CI] p** 
 n (%) n (%) n (%)   
Age      
<65 years 97 (47.5) 71 (53.0) 26 (37.1) 1.0  
≥65 years 107 (52.5) 63 (47.0) 44 (62.9) 1.973 [1.212-3.212] 0.006 
Sex      
Female 29 (14.2) 24 (17.9) 5 (7.1) 1.0  
Male 175 (85.8) 110 (82.1) 65 (92.9) 2.533 [1.018-6.303] 0.046 
Stage      
Ta 82 (40.2) 54 (40.3) 28 (40.0) 1.0  
T1 122 (59.8) 80 (59.7) 42 (60.0) 1.067 [0.661-1.723] 0.790 
Grade      
Low 55 (27.0) 36 (26.9) 19 (27.1) 1.0  
High 149 (73.0) 98 (73.1) 51 (72.9) 1.188 [0.700-2.017] 0.524 
Size (cm)      
<3 129 (67.9) 83 (66.4) 46 (70.8) 1.0  
≥3 61 (32.1) 42 (33.6) 19 (29.2) 0.828 [0.485-1.414] 0.490 
Tumor number      
Unifocal 96 (47.1) 68 (50.7) 28 (40.0) 1.0  
Multifocal 108 (52.9) 66 (49.3) 42 (60.0) 1.554 [0.963-2.510] 0.071 
CIS      
No 186 (91.2) 124 (92.5) 62 (88.6) 1.0  
Yes 18 (8.8) 10 (7.5) 8 (11.4) 1.238 [0.592-2.588] 0.570 
Recurrence Status      
Primary 104 (51.0) 72 (53.7) 32 (45.7) 1.0  
    Recurrent 100 (49.0) 62 (46.3) 38 (54.3) 1.304 [0.814-2.089] 0.270 
BCG schedule      
mBCG 138 (67.6) 101 (75.4) 37 (52.9) 1.0  
iBCG 66 (32.4) 33 (24.6) 33 (47.1) 2.034 [1.270-3.256] 0.003 
 
HR: Hazard Ratio; CI: Confidence Interval 
*
: Wald test; Bold values indicate p<0.05 
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Table 2 – Multivariate analysis and risk estimation of the most significant 
polymorphisms 
 HR
a 95%CI P value 
ICAM1  rs5498 A/G (K469E)    
AA 1.0 Referent - 
AG 0.821 [0.440-1.532] 0.536 
GG 1.678 [0.865-3.256] 0.125 
AA+AG 1.0 Referent - 
GG 1.759 [1.050-2.949] 0.032 
IL2RA rs2104286 C/T    
TT 1.0 Referent - 
CT 2.007 [1.207-3.335] 0.007 
CC 1.245 [0.476-3.257] 0.655 
CT+CC 1.603 [1.001-2.567] 0.050 
IL17A rs2275913 (-197G/A)    
GG 1.0 Referent - 
GA 0.856 [0.506-1.449] 0.562 
AA 1.946 [0.988-3.836] 0.054 
GG+GA 1.0 Referent - 
AA 2.097 [1.118-3.933] 0.021 
TNFA rs1799964 (-1031T/C)    
TT 1.0 Referent - 
TC 0.778 [0.458-1.324] 0.355 
CC 2.112 [0.970-4.598] 0.060 
TT+TC 1.0 Referent - 
CC 2.427 [1.144-5.149] 0.021 
CCR2 rs391835 G/A (V64I)    
GG 1.0 Referent - 
GA 0.816 [0.473-1.407] 0.055 
AA 0.410 [0.191-0.879] 0.022 
GA+AA 0.455 [0.232-0.893] 0.022 
TRAILR1 rs13278062 (-397T/G)    
TT 1.0 Referent - 
TG 3.546 [1.477-8.513] 0.005 
GG 3.078 [1.251-7.573] 0.014 
TG+GG 3.195 [1.373-7.433] 0.007 
HR: Hazard ratio; 95%CI: 95% Confidence Interval; a: adjusted to BCG scheme, age, gender and tumor 
multifocality. Bold values indicate p<0.05. 
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Table 3 – Predictive models of recurrence after BCG treatment obtain by Multivariate Stepwise 
Cox Regression 
 HR
 
95%CI P value c-index 
Model 1    0.698 
Age (<65 vs. ≥65) 1.78 [1.06-3.01) 0.031  
Gender (female vs. male) 2.72 [1.09-6.81] 0.033  
Tumor Number (unifocal vs. multifocal) 1.64 [0.97-2.76] 0.063  
Treatment Scheme (mBCG vs. iBCG) 2.01 [1.22-3.32] 0.006  
Model 2    0.735 
TNFA-1031T/C (rs1799964) (TT+TC vs. CC)  2.45 [1.31-5.33] 0.023  
IL4-33T/C (rs2070874) (CT vs. TT) 1.72 [0.86-3.38] 0.116  
IL2RA rs2104286 T/C (TT vs. TC+CC) 1.80 [1.08-2.99] 0.023  
IL17A-197G/A (rs2275913) (GG+GA vs. AA) 2.27 [1.16-4.45] 0.017  
IL17RA-809A/G (rs4819554) (AA+AGvs. GG) 2.19 [1.19-4.01] 0.011  
IL18R1 rs3771171 T/C (CC vs. TC+TT) 2.88 [0.88-9.47] 0.081  
IL6R Asp358Ala (rs8192284) (CC vs. CA+AA) 2.00 [0.85-4.67] 0.110  
ICAM1 K469E (rs5498) (AA+AG vs. GG) 1.87 [1.08-3.26] 0.027  
FASL-844T/C (rs763110) (TT+TC vs. CC) 1.71 [1.02-2.86] 0.041  
TRAILR1-397T/G (rs79037040) (TT vs. TG+GG) 2.59  [1.11-6.06] 0.028  
Model 3    0.820 
Gender (female vs. male) 4.45 [1.71-11.6] 0.002  
Tumor Number (unifocal vs. multifocal) 2.29 [1.37-3.84] 0.002  
Treatment Scheme (mBCG vs. iBCG) 3.57 [2.03-6.28] <0.001  
TNFA-1031T/C (rs1799964) (TT+TC vs. CC)  3.49  [1.58-7.70] 0.002  
IL4-33T/C (rs2070874) (CT vs. TT) 1.93 [0.96-3.86] 0.065  
IL2RA rs2104286 T/C (TT vs. TC+CC) 2.79 [1.63-4.78] <0.001  
IL17A-197G/A (rs2275913) (GG+GA vs. AA) 2.65 [1.32-5.32] 0.006  
IL17RA-809A/G (rs4819554) (AA+AG vs. GG) 2.89 [1.49-5.63] 0.002  
IL18R1 rs3771171 T/C (CC vs. TC+TT) 2.75 [0.82-9.18] 0.101  
ICAM1 K469E (rs5498) (AA+AG vs. GG) 2.47 [1.42-4.29] 0.001  
FASL-844T/C (rs763110) (TT+TC vs. CC) 1.70 [1.02-2.84] 0.042  
TRAILR1-397T/G (rs79037040) (TT vs. TG+GG) 5.19 [2.05-13.1] 0.001  
HR: Hazard ratio; 95%CI: 95% Confidence Interval.  
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Table 4. Patients distribution among the risk groups and risk assessment of each group. 
 Total BCG success BCG failure HR 95% CI p
* 
 n (%) n (%) n (%)    
Low RisK 90 (44.1) 83 (61.9) 7 (10.0) 1.0 Referent - 
Intermediate Risk 69 (33.8) 40 (29.9) 29 (41.4) 6.58 [2.88-15.1] <0.001 
High Risk 45 (22.1) 11 (8.2) 34 (48.6) 18.7 [8.24-42.6] <0.001 
 
HR: Hazard Ratio; CI: Confidence Interval; 
*
: Wald test 
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